At Probius, we imagine a world where decentralized and predictive healthcare helps people stay ahead of disease.

This requires an easily accessible, no-constraints approach to the acquisition of robust, biological data.

To that end, we have pioneered a new bioanalytical technology called QES, and coupled it with AI-powered software.

By making biochemical data easier to access and easier to use in AI workflows, we can help find detailed and predictive insights into diseases faster and thereby also accelerate drug development.

We are empowering the future of life science research. This will usher in a decentralized model for healthcare, where samples are processed closer to the patient, making insights actionable faster.

Bridging biology and AI, to improve human health

Our values

Commitment

We help our customers and partners advance their field. Providing data-driven workflows and solutions, with a commitment to the relationships we build.

Innovation

We strive to extend the boundaries of what is possible. We help our partners and customers solve projects at all levels of complexity.

Collaboration

We foster the spirit of innovation by promoting open-mindedness and collaboration. We build upon our shared scientific knowledge, to take responsible risks together.

Mission-driven

We challenge ourselves to think beyond the status quo, to enable human wellness through technological and scientific discoveries.

Leadership

Management Team

Emmanuel Quevy, CEO Profile picture

Emmanuel Quevy, Ph.D.

Co-founder and CEO
Chaitanya Gupta, CTO,

Chaitanya Gupta, Ph.D.

Co-founder and CTO

John Baldoni CSO

John Baldoni, Ph.D.

Chief Scientific Officer

Juan Cuevas SVP Marketing

Juan Cruz Cuevas, Ph.D

SVP of Marketing & BD

Board of Directors

Emmanuel Quevy, CEO Profile picture

Emmanuel Quevy, Ph.D.

Co-founder and CEO
Chaitanya Gupta, CTO,

Chaitanya Gupta, Ph.D.

Co-founder and CTO

Jason Paragas, Independent Board Director

Jason Paragas, Ph.D.

Independent Director

John MacWilliams, Independent Board Director

John J. MacWilliams

Independent Director

Janis Naeve, Board Director representing Cota Capital

Janis Naeve, Ph.D.

Director

Neil Mody, Board Observer

Neal Mody

Board Observer

Sandi LI, Board Observer

Sandy Li, Ph.D.

Board Observer

Advisors

Roger Howe, Advisor and FOunder

Roger Howe, Ph.D.

Co-founder and Technology Advisor

Margaret Landi, VMD, DACLAM, MBioethics

Scientific Advisor

Anne-Marie Martin, Ph.D.

Scientific Advisor

Ross Walker, Ph.D.

Scientific Advisor

Odilo Mueller, Ph.D.

Advisor
Rahul Dhanda
Advisor

Investors & Partners

We’re honored to work with a world-class group of investors.

Emmanuel Quevy, Ph.D.

Co-founder and CEO

Emmanuel P. Quevy, Ph.D. is co-founder and CEO of Probius, where he applies his expertise in advanced sensor products and technologies and his experience in entrepreneurship and technology transition to commercial scale. Prior to founding Probius, he was responsible for engineering and technology at SDI where he oversaw product and technology roadmaps of inertial guidance systems and managed strategic customer programs with Boeing, the US Navy, and other key accounts. Prior to that, he was co-founder, president and CTO of Silicon Clocks, which was acquired in 2010 by Silicon Laboratories (NASDAQ:SLAB) and where he served as director of MEMS engineering for timing products.


Dr. Quevy’s 20 years of experience in the design and integration of complex sensor technologies include co-authoring more than 40 publications, co-inventing more than 40 issued US patents, and serving as a reviewer and committee member of various journals and conferences. 


His engineering degree from ISEN Lille, France, and M.Sc. degree in electrical engineering and computer science from the University of Science and Technology of Lille (USTL), France, preceded his Ph.D. degree in electrical engineering from UST, with post-doctoral work at The Berkeley Sensor and Actuator Center where he led the DARPA-funded IMT program.

Chaitanya Gupta, PhD

Co-founder and CTO

Chaitanya Gupta, Ph.D. is co-founder, president, and CTO of Probius. While Senior Research Engineer at Stanford University, in the research group of Prof. Roger T. Howe, he invented the all-electronic molecular analyzer that forms the basis of Probius’ technology. He is now responsible for the development and validation of the company’s novel bioanalytical platform.


His research interests lie at the intersection of surface science, electrical engineering, and quantum statistical physics, developing novel sensing paradigms that can be applied for improved clinical diagnostics, bio-surveillance, and facilitating low-cost and efficient pharma-focused clinical trials. Dr. Gupta has authored eleven publications, presented at thirty conference meetings, and is an inventor on four patents associated with the all-electronic molecular analyzer. 


Dr. Gupta received a B.Tech in Chemical Engineering from the Indian Institute of Technology, which was followed by an M.S. and Ph.D. in Chemical Engineering from the University of Illinois at Urbana-Champaign. He also minored in Physics in graduate school and was awarded an M.S. for the same in 2009.

John Baldoni, Ph.D.

Chief Scientific Officer

John Baldoni, Ph.D. is Probius’ Chief Scientific Officer (CSO) and Chairman of the Scientific Advisory Board (SAB). Dr. Baldoni also holds positions as co-founder and Chief Scientific Officer of SaponiQx and is CEO of the Atom Research Alliance.


John has worked in the pharmaceutical industry for nearly 40 years, his work spanning roles such as new chemical entity design, development and commercialization, and biopharmaceutical development. He spent 29 years in GSK’s Research and Development organization, 11 of which were on its executive leadership team. As SVP of Platform Technology and Science, he started the first AI-driven drug discovery unit at GSK. Other positions held included Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional strategic initiatives, such as advanced manufacturing technologies and discovery modernization. 


John has a BS in biochemistry (1974), and MS and Ph.D. degrees in chemistry (1980) from Penn State University.

Juan Cruz Cuevas

SVP of Marketing and Business Development

Juan Cruz Cuevas is the SVP of Marketing and Business Development at Probius. Juan is a dynamic and customer-focused leader in the life science field with more than a decade of experience. Passionate about introducing disruptive technologies, he has led commercialization projects in several commercially successful companies, each of which were in a variety of stages and from different areas of biology and health. 

 

Juan’s career has focused on customer experience, sales, business development, product management, and product marketing for providers of disruptive technologies instruments, reagents, services, and software with a focus on genomics, proteomics, clinical applications, and diagnostics. Juan has led and contributed to the launch of several products, and commercial strategies with a positive impact on revenue and value creation for shareholders. He earned a bachelor’s degree in Biochemistry from the Universidad Nacional de Cordoba, Argentina, an MS and Ph.D. in Pharmacy and Nutrition from Universitat de Barcelona, Spain, and a master’s in biotechnology management by the IE Business School in Madrid, Spain.

Jason Paragas, Ph.D.

Independent Director

Jason Paragas, Ph.D. is Venture Partner with Social Impact Capital. Until recently, he was the Vice-President of Strategic Initiatives at Agenus (NASDAQ:AGEN), a co-founder of SaponiQx, and Vice President for External Innovation at Valo Health. While Director of Innovation at Lawrence Livermore National Laboratory, he helped create AI-based projects for precision medicine.

 

Dr. Paragas has been a technical advisor to leaders at the Department of Energy, and led the Ebola virus Task Force, for which he was awarded a Secretary of Energy Appreciation Award. During his tenure as Senior Advisor in the Department of Defense, he led the development of the strategic architecture for the next generation of diagnostics, bio-surveillance, and medical countermeasures for science and technology investments. Prior, he was the Associate Director for Science at the Integrated Research Facility, NIAID, served on multiple government advisory groups, and received multiple Secretary of Energy appreciation awards. 

 

Jason holds a Ph.D. degree in Microbiology from the Icahn School of Medicine at Mount Sinai.

John J. MacWilliams

Independent Director

John J. MacWilliams is a Senior Advisor to the Director at Lawrence Livermore National Laboratory. He has also served as Special Assistant to President for National Security Affairs and Senior Advisor to the Homeland Security Advisor in the Biden Administration. Prior to accepting those positions, he held senior roles at the Center on Global Energy Policy, the Boston Consulting Group, and at Livermore National Laboratory. During the Obama Administration, Mr. MacWilliams served as Associate Deputy Secretary and Chief Risk Officer of the U.S. Department of Energy.  


Earlier positions included: Partner, Tremont Energy Partners, LLC (a private investment firm); Vice Chairman, Investment Banking, at JP Morgan Chase; founding partner of The Beacon Group, LLC, (which was acquired by JPMorgan Chase); head of Goldman Sachs’ international structured finance group; and as an attorney at Davis Polk & Wardwell. 


He holds a B.A. from Stanford University, an M.S. from Massachusetts Institute of Technology, and a J.D. from Harvard Law School. 

Janis Naeve Ph.D.

Director

Janis Naeve Ph.D.  is a Partner at Cota Capital, which focuses on innovation for better health care, and which lead the Series A investment in Probius. She previously worked at Amgen, establishing the corporate ventures group Amgen Ventures. Here she led a team that invested in innovative companies developing drug discovery platforms and therapeutics. Amgen Ventures’ investment portfolio also encompassed companies in digital health, healthcare IT, and advanced data analytics such as AI and machine learning.

 

In addition to nearly two decades in biotech investing, Dr. Naeve served as the Director of Business Development for several biotech companies, including X-Ceptor Therapeutics and Aurora Biosciences. 


She holds a Ph.D. in Experimental Pathology from USC and earned a Postdoctoral Fellowship focused on Neurobiology from the California Institute of Technology. She is the recipient of the 2021 Fiercest Women in Life Science award.

Neal Mody

Board Observer

Partner and Managing director of Zoic Capital, a firm investing in seed stage to series A med-tech companies.

Sandy Li, PhD

Board Observer

VP, Strategy and Investments / Managing Director of BioMap Ventures.

Roger Howe, Ph.D.

Co-founder and Technology Advisor

Roger T. Howe, Ph.D. is co-founder of Probius and serves as scientific advisor. Roger is currently the William E. Ayer Professor of Electrical Engineering at Stanford University. He has also held faculty positions at Carnegie-Mellon University, the Massachusetts Institute of Technology, and UC Berkeley, where he was the Robert S. Pepper Distinguished Professor. His research interests include micro electromechanical system design and micro- and nano-machining technologies; he is currently focused on biochemical sensing applications using electronic tunneling spectroscopy and droplet-based ferro-microfluidic systems for rare cell classification. 


Dr. Howe was elected an IEEE Fellow in 1996 and was co-recipient with Richard S. Muller of the IEEE Cledo Brunetti Award. Additionally, he was elected to the U.S. National Academy of Engineering “for contributions to the development of microelectromechanical systems in processes, devices and systems.” He has also served as Director of the U.S. National Nanotechnology Infrastructure Network (NNIN) and as the Faculty Director of the Stanford Nanofabrication Facility (SNF). He co-founded two companies based on research in his group. Silicon Clocks, Inc., which was acquired by Silicon Labs, Inc., and ProbiusDx, Inc. 


He earned a B.S. degree in physics from Harvey Mudd College and M.S. and Ph.D. degrees in electrical engineering from the University of California, Berkeley (1974), and MS and Ph.D. degrees in chemistry (1980) from Penn State University.

Margaret Landi, VMD, DACLAM, MBioethics

Scientific Advisor

Chief Veterinarian, GSK Pharmaceuticals.

Anne-Marie Martin, PhD

Scientific Advisor

SVP and Global Head of the Experimental Medicine Unit in Oncology R&D at GSK.

Ross Walker Ph.D.

Scientific Advisor

Ross Walker, Ph.D. is an advisor to Probius on state-of-the-art data science approaches, scalable data systems, and high-performance computing.


Dr. Walker has over 20 years of experience leading both US Government and commercial efforts in high-performance and data-intensive computing in the life sciences. He has held the roles of Vice President of Research Computing & Data Science at Agenus Inc, Global Head of Scientific Computing at GlaxoSmithKline, and Biosciences Lead & Director of the Parallel Computing Center of Excellence at the San Diego Supercomputer Center. He has led teams with world-class expertise in scientific computing and AI. His expertise is in the design, development, and deployment of cutting-edge computing resources, hardware, and software to enable the rapid discovery and development of successful medicines. Ross is also an Adjunct Professor of Chemistry & Biochemistry at UC San Diego, an Affiliate Scientist at the San Diego Supercomputer Center, and a Fellow of NVIDIA Inc.


Born in London, England, he studied at Imperial College London, graduating summa cum laude with an MSci in Chemistry and Ph.D. in Quantum Chemistry before relocating to the United States to embark on a career in scientific research. Ross is the author of over 80 peer-reviewed articles and collected works, as well as a principal developer of the AMBER Molecular Dynamics software, used in over 1000+ research labs and pharmaceutical companies worldwide. In his Free TimeTM Ross is an avid cave and technical scuba diver.

Odilo Mueller, PhD

Co-founder and CEO

Founder and President at CYTO Consulting, former marketing executive at AbCam, Millipore and Agilent.

Rahul Dhanda

Advisor

25 years experience, executive in private and publicly traded companies, including Founding CEO of Sherlock Biosciences, SVP at T2 Biosystems.